Odile Jaume to Lead Telix’s European Operations
News,
Telix Pharmaceuticals Limited is delighted to announce the appointment of Ms. Odile Jaume as President and Chief Operating Officer (COO) of Telix’s European…
Read moreNews & Views
Telix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives
News,
Telix Pharmaceuticals Limited is pleased to announce the establishment Telix Pharmaceuticals (Japan) Ltd and appointment of the first two members of the Japanese leadership…
Read more
Telix Pharmaceuticals and Memorial Sloan Kettering Cancer Center Announce Renal Cancer Collaboration
Telix has today announced a collaboration with Memorial Sloan Kettering Cancer Center…
Read more
Telix Pharmaceuticals Appointed Dr. Bernard Lambert as President of Telix Pharmaceuticals (US) Inc.
News,
Telix has today announced the appointment of Dr. Bernard Lambert as President and Chief Operating Officer (COO) of Telix’s US…
Read more
Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering
Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised…
Read more Telix Pharmaceuticals and AMNI Partner for Prostate Cancer Imaging
Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA…
Read more Telix Pharmaceuticals Launches $50M Underwritten Initial Public Offering
Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50…
Read more Telix and University of Melbourne Establish Cancer Translational Research Partnership
Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of…
Read more Telix Pharmaceuticals files $50M Underwritten Initial Public Offering
Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public…
Read more Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology
Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology…
Read more